Table 2 Demographic and clinical characteristics at initiation of combination antiretroviral therapy by regimen^a

 Age

40 (33–47)

40 (33–47)

40 (32–46)

0.25

38 (32–45)

39 (32–46)

0.49

  < 35

601 (30%)

521 (29%)

80 (36%)

0.03

189 (35%)

69 (38%)

0.02

 35–44

746 (37%)

680 (38%)

66 (30%)

217 (40%)

53 (29%)

  ≥ 45

666 (33%)

590 (33%)

76 (34%)

138 (25%)

61 (33%)

 Male

1632 (81%)

1439 (81%)

193 (87%)

0.02

434 (80%)

162 (89%)

<.01

 Female

373 (19%)

344 (19%)

29 (13%)

<.0001

110 (20%)

21 (11%)

<.01

 MSM

764 (38%)

646 (36%)

118 (53%)

293 (54%)

113 (62%)

 Male, not MSM

479 (24%)

451 (25%)

28 (13%)

93 (17%)

22 (12%)

 Missing

397 (20%)

350 (20%)

47 (21%)

48 (9%)

27 (15%)

 White

531 (26%)

492 (27%)

39 (18%)

<.001

146 (27%)

34 (19%)

<.0001

 Black

128 (6%)

117 (7%)

11 (5%)

84 (15%)

11 (6%)

 Aboriginal Peoples

109 (5%)

101 (6%)

8 (4%)

11 (2%)

7 (4%)

 Other

145 (7%)

133 (7%)

12 (5%)

41 (8%)

9 (5%)

 Missing

1100 (55%)

948 (53%)

152 (68%)

262 (48%)

122 (67%)

 No

1207 (60%)

1053 (59%)

154 (69%)

<.0001

426 (78%)

142 (78%)

0.03

 Yes

542 (27%)

521 (29%)

21 (9%)

59 (11%)

11 (6%)

 Missing

264 (13%)

217 (12%)

47 (21%)

59 (11%)

30 (16%)

 No

537 (27%)

406 (23%)

131 (59%)

<.0001

406 (75%)

131 (72%)

0.02

 Yes

99 (5%)

80 (4%)

19 (9%)

80 (15%)

19 (10%)

 Missing

1377 (68%)

1305 (73%)

72 (32%)

58 (11%)

33 (18%)

 British Columbia

1286 (64%)

1247 (70%)

39 (18%)

<.0001

--

--

 Ontario

355 (18%)

264 (15%)

91 (41%)

264 (49%)

91 (50%)

0.78

 Quebec

372 (18%)

280 (16%)

92 (41%)

280 (51%)

92 (50%)

 No

1349 (67%)

1168 (65%)

181 (82%)

<.0001

449 (83%)

155 (85%)

0.75

 Yes

559 (28%)

530 (30%)

29 (13%)

71 (13%)

20 (11%)

 Missing

105 (5%)

93 (5%)

12 (5%)

24 (4%)

8 (4%)

CD4 count (cells/mm³)

220 (120–330)

220 (120–320)

280 (130–370)

<.01

230 (149–310)

286 (130–370)

<.01

<200

869 (43%)

795 (44%)

74 (33%)

<.001

214 (39%)

60 (33%)

<.0001

200–349

693 (34%)

620 (35%)

73 (33%)

234 (43%)

60 (33%)

350–499

287 (14%)

237 (13%)

50 (23%)

69 (13%)

45 (25%)

≥500

164 (8%)

139 (8%)

25 (11%)

27 (5%)

18 (10%)

Log 10 (VL copies/mL)

4.91 (4.41–5.11)

4.90 (4.42–5.05)

4.94 (4.36–5.44)

0.03

4.82 (4.35–5.26)

4.90 (4.26–5.39)

0.43

VL ≥ 100,000 copies/mL

881 (44%)

780 (44%)

101 (45%)

0.58

209 (38%)

77 (42%)

0.38

Year of cART initiation

2009 (2007–2010)

2008 (2006–2010)

2011 (2010–2011)

<.0001

2008 (2007–2009)

2010 (2010–2011)

<.0001

2003–2006

474 (24%)

473 (26%)

1 (0%)

<.0001

121 (22%)

1 (1%)

<.0001

2007–2009

799 (40%)

767 (43%)

32 (14%)

307 (56%)

32 (17%)

2010–2012

740 (37%)

551 (31%)

189 (85%)

116 (21%)

150 (82%)

 3TC/ABA

499 (25%)

441 (25%)

58 (26%)

<.0001

259 (48%)

53 (29%)

<.0001

 3TC/TDF

285 (14%)

284 (16%)

1 (0%)

36 (7%)

1 (1%)

 FTC/TDF

1172 (58%)

1009 (56%)

163 (73%)

230 (42%)

129 (70%)

 Other

57 (3%)

57 (3%)

0 (0%)

19 (3%)

0 (0%)

 Years of Follow up

3.10 (1.45–5.16)

3.50 (1.63–5.38)

1.48 (0.69–2.25)

<.0001

3.73 (2.20–5.32)

1.68 (0.86–2.46)

<.0001

 VLs per year

4.67 (3.61–6.21)

4.68 (3.63–6.16)

4.50 (3.55–6.56)

0.71

3.88 (3.12–4.76)

4.32 (3.44–5.76)

<.001

 0–3

274 (14%)

246 (14%)

28 (13%)

0.43

121 (22%)

26 (14%)

<.001

 3–6

1187 (59%)

1062 (59%)

125 (56%)

358 (66%)

115 (63%)

  > 6

552 (27%)

483 (27%)

69 (31%)

65 (12%)

42 (23%)